HOME > Business Wire > Article
Cardio Diagnostics Secures Japanese Patent for AI-Driven Cardiovascular Disease Detection Technology
CHICAGO--( BUSINESS WIRE )-- Cardio Diagnostics Holdings Inc. (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced that the Japan Patent Office has issued a patent for another set of biomarkers in the company’s intellectual property portfolio. The patent, titled “Compositions and Methods for Detecting Predisposition to Cardiovascular Disease,” (Japanese Patent No. 7672192) is exclusively licensed to Cardio Diagnostics from the University of Iowa Research Foundation (UIRF) and names Cardio Diagnostics’ founders Meesha Dogan, Ph.D., Chief Executive Officer, and Robert Philibert, MD, Ph.D., Chief Medical Officer, as inventors.
The Japanese patent further strengthens Cardio Diagnostics’ global IP strategy and adds to its robust portfolio of issued patents in the United States, Europe, Australia, India, and China, covering core technologies that helped yield the Company’s clinical solutions.
“Receiving this patent in Japan marks a critical milestone in our mission to globalize our precision cardiovascular medicine platform,” said Meesha Dogan, Ph.D., CEO of Cardio Diagnostics. “As cardiovascular disease continues to rise in prevalence worldwide, the ability to offer AI-powered, methylation- and genetics-based diagnostics in international markets like Japan represents a major step forward in improving early detection and prevention of heart disease.”
“We are proud to support this important innovation from the University of Iowa ecosystem,” said Marie Kerbeshian, Ph.D., Executive Director of the UIRF. “Cardio Diagnostics continues to demonstrate the global relevance of its technology, and we look forward to the impact it will have in advancing cardiovascular medicine across borders.”
The Japanese patent protects Cardio Diagnostics’ novel methods and compositions that enable the detection of cardiovascular disease risk and presence using epigenetic and genetic biomarkers interpreted through advanced machine learning algorithms. This issuance underscores the global applicability of the Company’s pioneering approach to heart disease prevention.
As part of its expanding IP footprint, Cardio Diagnostics is committed to delivering innovative, data-driven solutions that empower healthcare providers and patients with actionable insights for cardiovascular health, now on a global scale.
About Cardio Diagnostics
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit https://cdio.ai/
Forward-Looking Statements
Certain statements and information included in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, “will likely result,” “expected to,” “will continue,” “anticipated,” “estimate,” “projected,” “intend,” “goal,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on results are discussed in the Current Report on Form 10-K for the period ended in December 31, 2024, and Form 10-Q for the period ended in March 31, 2025, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed within this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250610505138/en/
Contacts
Investors
Investor Relations
855-226-9991
investors@cdio.ai
Media & Public Relations
Public Relations
855-226-9991
pr@cdio.ai
Source: Cardio Diagnostics Holdings Inc.
Business Wire
-
06/19 02:00 New Murata Automotive-Compliant Chip Ferrite Beads Deliver Wide Band N...
-
06/19 02:00 Toshiba Releases 2-Channel Automotive Standard Digital Isolators Compl...
-
06/19 02:00 Juniper Networks Wins Four Awards at Interop Tokyo 2025
-
06/18 17:29 JCR Pharmaceuticals Announces Launch of Mucopolysaccharidosis (MPS) Ty...
-
06/18 15:00 Yamaha Music Innovations Partners Up with Four Startup Companies
-
06/18 13:00 Nippon Steel Corporation and U. S. Steel Finalize Historic Partnership
-
06/18 07:00 Nidec Announces Change in the Scheduled Submission Date for the Securi...
-
06/18 06:00 Yokogawa Collaborates with Shell on Robotics and AI Technology for Pla...
-
06/18 03:00 Mitsubishi Electric Develops Edge-device Language Model for Domain-spe...
-
06/18 01:30 DNP to Take Controlling-Stake in Laxton
-
06/18 01:20 DNP: Operational Launch of 2,500 mm-Width Coating Line to Enhance Prod...
-
06/17 13:00 OSG Corporation Extends its Contract with Rimini Street for Support of...
-
06/17 12:07 Celltrio Secures $15 Million Financial Investment to Accelerate Global...
-
06/17 12:00 NTT DATA Research Reveals C-Suite Misalignment Over GenAI Adoption
-
06/17 10:50 Daimler Truck, Mitsubishi Fuso, Hino and Toyota Motor Corporation Conc...
-
06/17 04:00 Agileo Automation Announces Future Expansion Of A2ECF-SEMI Automation ...
-
06/16 14:00 Yamaha Motor Makes First International Delivery of CELL HANDLER 2 to U...
-
06/16 06:00 Wisk and Japan Airlines Engineering Sign Memorandum of Understanding w...
-
06/16 05:00 HekaBio, Japan-based Biopharma and MedTech Platform, Enters Strategic ...
-
06/15 23:00 Both ISS and Glass Lewis Recommend Shareholders Vote AGAINST Keisei Pr...
-
06/15 09:00 FANTASTICS from EXILE TRIBE, Former Taipei City Tourism Ambassadors, t...
-
06/13 23:00 President Trump Approves Historic Partnership between U. S. Steel and ...
-
06/13 13:00 Capcom’s Devil May Cry 5 Sales Top 10 Million Units!
-
06/13 12:00 As Markets Teeter, EBC’s David Barrett Calls for Caution, Lower Leve...
-
06/13 02:00 Notice Regarding Conviction of Three Chinese Companies That Produced a...
-
06/13 02:00 Kao Releases the Kao Integrated Report 2025
-
06/13 02:00 Kao Releases Kao Sustainability Report 2025
-
06/12 20:17 KBRA Expands Global Footprint With Opening of First Asia-Pacific Offic...
-
06/12 14:00 Rigaku Launches Fourth Generation Handheld 1064 nm Raman Analyzer for ...
-
06/12 13:30 CADDi Strengthens Strategic Partnership With Google Cloud, Enters Goog...